When is Ceribell the better choice?

The hardware exists to serve the algorithm rather than the other way round, letting a non specialist place a headband and get an interpreted result where a conventional study needs a technologist and a neurologist. A clear regulatory leader in its niche with a progression of clearances including age specific expansions, which functions as de facto evidence that performance was examined per population. The algorithm's operation is described with unusual specificity, interpreting continuously across channels to produce a burden estimate rather than a single classification.

When is VUNO the better choice?

It uses only four routinely charted vital signs, so there is no device to buy, no consumable and no new workflow, and the model consumes what the record already contains. The evidence is genuinely independent and multicentre across several tertiary hospitals, which addresses site level generalisability better than most deterioration models in this index. Inputs and outputs are stated precisely, four named vital signs producing a bounded score over a defined horizon, so a clinical team knows exactly what the number means.

Ceribell vs VUNO

Last VerifiedAugust 4, 2026

Verdict

Two acute risk algorithms with opposite hardware answers, which is the useful thing about putting them side by side. Ceribell brings its own instrument: a rapidly placed headband feeding a machine learning model that estimates seizure burden and alerts clinicians to suspected status epilepticus, in departments where no neurologist is standing by. VUNO brings nothing at all, predicting in hospital cardiac arrest within a day from four vital signs the ward already charts, with independent multicentre validation across several tertiary hospitals. Neither competes with the other clinically. What they illustrate together is the trade every acute prediction buyer makes: a device gives you a signal nobody currently collects and a cost per patient, while a model over existing data is free of consumables and limited to what the chart already knows.

Select Ceribell if

The hardware exists to serve the algorithm rather than the other way round, letting a non specialist place a headband and get an interpreted result where a conventional study needs a technologist and a neurologist.
A clear regulatory leader in its niche with a progression of clearances including age specific expansions, which functions as de facto evidence that performance was examined per population.
The algorithm's operation is described with unusual specificity, interpreting continuously across channels to produce a burden estimate rather than a single classification.

Select VUNO if

It uses only four routinely charted vital signs, so there is no device to buy, no consumable and no new workflow, and the model consumes what the record already contains.
The evidence is genuinely independent and multicentre across several tertiary hospitals, which addresses site level generalisability better than most deterioration models in this index.
Inputs and outputs are stated precisely, four named vital signs producing a bounded score over a defined horizon, so a clinical team knows exactly what the number means.

Attribute Matrix

Side by Side

Axis	C Ceribell	V VUNO
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.

Abstractive Health vs xCures→AccurKardia vs Eko Health→AccurKardia vs HeartSciences→AgileMD vs Bayesian Health→Aidoc vs Bunkerhill Health→Aidoc vs Qure AI→

Disclosure

These products address different clinical questions, seizure detection at the point of care and cardiac arrest prediction on the ward, and are compared here because both are algorithm led acute risk products, not because a hospital would choose between them. Regulatory status differs by product and jurisdiction for both vendors and should be checked per product rather than per company. Neither publishes a business associate posture, and neither publishes hosting or residency detail. VUNO's validation is Korean, so a United States buyer should ask what performance looks like in a population with different baseline vital sign distributions and different escalation practices.